Safety monitoring of a bowel inflammation treatment in real-world patient care

This is a safety monitoring study of tofacitinib, a medication used to treat moderate-to-severe ulcerative colitis (a type of inflammatory bowel disease). Researchers will collect medical information from patients across the European Union who are taking tofacitinib and compare them to patients taking other approved treatments or newer patients who haven't yet started treatment. The goal is to understand how safe this medication is when used in everyday clinical practice over several years.

Although this medication was approved for ulcerative colitis, regulators want to ensure it remains safe when used by many different patients in real-world settings. This study will track whether serious but rare side effects—such as certain cancers or blood clots—occur and at what rate, compared to patients using other treatments.